Open AccessEvaluation of the safety and efficacy of corifollitropin alfa combined with GnRH agonist triggering in oocyte donation cycles. A prospective longitudinal study
Author(s) -
Ioannis Tsakiridis,
Robert Najdecki,
Petroula Tatsi,
Evangelia Timotheou,
Kallirhoe Kalinderi,
Georgios Michos,
Andriana Virgiliou,
Hakan Yaralı́,
Apostolos Athanasiadis,
Evangelos Papanikolaou
Publication year - 2020
Publication title -
jbra
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 14
eISSN - 1518-0557
pISSN - 1517-5693
DOI - 10.5935/1518-0557.20200033
Subject(s) - agonist , oocyte donation , donation , oocyte , andrology , medicine , gynecology , biology , embryo , receptor , microbiology and biotechnology , economic growth , economics
In order to help make the dream of parenthood come true for oocyte acceptors, it is essential that the procedure is not dangerous or unpleasant for oocyte donors. The aim of this study was to identify differences in safety, efficacy and patient acceptability between a traditional stimulation antagonist protocol with recombinant-FSH (rFSH) with hCG-triggering, compared with an innovative antagonist protocol with corifollitropin alfa (Elonva®) plus GnRH agonist triggering in oocyte donors.